醫療保健 · Healthcare
開啟互動頁面（K 線、成交價圖）Open interactive page →
RXRX · RECURSION PHARMACEUTICALS, INC.
內部人交易（Form 4）· Insider trading · 2026-07-01 – 2026-10-22
RECURSION PHARMACEUTICALS, INC.（RXRX）內部人交易：2026-07-01 至 2026-10-22，內部人公開市場買入 —、賣出 $802K；高管董事有效買入 —、有效賣出 —。最近申報 2026-10-07。
買入 Bought—
賣出 Sold$802K
有效買入 Effective bought—
有效賣出 Effective sold—
最近申報 Recent filings
| 交易日 | 內部人 | 類型 | 股數 | 價格 | 金額 | |
|---|---|---|---|---|---|---|
| 2026-10-06 | Borgeson Blake Director | 賣出 Sell | 50,000 | $4.84 | $242K | SEC |
| 2026-10-06 | HERSHBERG ROBERT Director | 賣出 Sell | 25,000 | $5.00 | $125K | SEC |
| 2026-09-08 | Khan Najat CEO and President, Director | 賣出 Sell | 22,408 | $3.52 | $79K | SEC |
| 2026-09-01 | Borgeson Blake Director | 賣出 Sell | 30,000 | $3.34 | $100K | SEC |
| 2026-08-04 | Borgeson Blake Director | 賣出 Sell | 30,000 | $3.25 | $98K | SEC |
| 2026-07-07 | Borgeson Blake Director | 賣出 Sell | 40,000 | $3.96 | $158K | SEC |
「有效」= 高管或董事的公開市場主動買賣，排除 10b5-1 計劃、行權賣出、繳稅賣出、IPO/認購等。
擬出售 Form 144
| 預計出售日 | 申報人 | 股數 | 約金額 | |
|---|---|---|---|---|
| 2026-10-06 | Borgeson Blake Director | 50,000 | $242K | 10b5-1 |
| 2026-10-06 | HERSHBERG ROBERT Director | 25,000 | $125K | 10b5-1 |
| 2026-09-08 | Khan Najat Officer | 22,408 | $79K | 10b5-1 |
| 2026-09-01 | Borgeson Blake Director | 30,000 | $100K | 10b5-1 |
| 2026-08-21 | Gibson Christopher Former Director | 77,290 | $262K | |
| 2026-08-20 | Gibson Christopher Former Director | 75,000 | $255K | |
| 2026-08-19 | Gibson Christopher Former Director | 100,000 | $328K | |
| 2026-08-18 | Gibson Christopher Former Director | 26,806 | $80K | |
| 2026-08-13 | Gibson Christopher Former Director | 100,000 | $331K | |
| 2026-08-12 | Gibson Christopher Former Director | 50,000 | $168K |
內部人 Insiders
Borgeson Blake、HERSHBERG ROBERT、Khan Najat